(59 days)
The GEM Premier 5000 is a portable critical care system for use by health care professionals to rapidly analyze heparinized whole blood samples at the point of health care delivery in a clinical setting and in a central laboratory. The instrument provides quantitative measurements of pH, pCO2, pO2, sodium, potassium, chloride, ionized calcium, glucose, lactate, hematocrit, total bilirubin and CO-Oximetry (tHb, O2Hb, MetHb, HHb, sO2*) parameters from arterial, venous or capillary heparinized whole blood. These parameters, along with derived parameters, aid in the diagnosis of a patient's acid/base status, electrolyte and metabolite balance and oxygen delivery capacity. *sO2 = ratio between the concentration of oxyhemoglobin and oxyhemoglobin plus deoxyhemoglobin.
· pH, pCO2, and pO2 measurements in whole blood are used in the diagnosis and treatment of life-threatening acid-base disturbances.
· Electrolytes in the human body have multiple roles. Nearly all metabolic processes depend on or vary with electrolytes:
· Sodium (Na+) measurements are used in the diagnosis and treatment of aldosteronism, diabetes insipidus, adrenal hypertension, Addison's disease, dehydration, inappropriate antidiuretic secretion, or other diseases involving electrolyte imbalance.
· Potassium (K+) measurements are used to monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.
• Ionized calcium (Ca++) measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.
• Chloride (Cl-) measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders, such as cystic fibrosis and diabetic acidosis.
· Hematocrit (Hct) measurements in whole blood of the packed red cell volume of a blood sample are used to distinguish normal from abnormal states, such as anemia and erythrocytosis (an increase in the number of red cells),
· Glucose (Glu) measurement is used in the diagnosis, monitoring and treatment of carbohydrate metabolism disturbances including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma.
· Lactate (Lac) measurement is used:
· to evaluate the acid-base status of patients suspected of having lactic acidosis;
· to monitor tissue hypoxia and strenuous physical exertion:
· in the diagnosis of hyperlactatemia.
· Total Bilirubin (tBili) measurement is used to aid in assessing the risk of kernicterus and hyperbilirulyinemia in neonates.
• CO-Oximetry (tHb, COHb, MetHb, O2Hb, HHb, and sO2) evaluates the ability of the blood to carry oxygen by measuring total hemoglobin and determining the percentage of functional hemoglobin species.
• Total Hemoglobin (tHb): Total hemoglobin measure the hemoglobin content of whole blood for the detection of anemia.
· COHb: Carboxyhemoglobin measurements are used to determine the carboxyhemoglobin content of human blood as an aid in the diagnosis of carbon monoxide poisoning.
· MetHb: Methemoglobin measurements are used to determine different conditions of methemoglobinemia.
· HHb: Deoxyhemoglobin, as a fraction of total hemoglobin, is used in combination with oxyhemoglobin to measure oxygen status.
· O2Hb: Oxyhemoglobin, as a fraction of total hemoglobin, is used in combination with decxyhemoglobin to measure oxygen status.
· sO2: Oxygen saturation, more specifically the ratio between the concentration of oxyhemoglobin and oxyhemoglobin plus deoxyhemoglobin, is used to measure oxygen status.
The GEM Premier 5000 system provides health care professionals with fast, accurate, quantitative measurements of pH, pCO2, pO2, sodium, potassium, chloride, ionized calcium, glucose, lactate, hematocrit, total bilirubin and CO-Oximetry (tHb, O₂Hb, MetHb, HHb, sO₂*) parameters from arterial, venous or capillary heparinized whole blood in central laboratory or point-of-care clinical settings.
*sO2 = Ratio between the concentration of oxyhemoglobin plus deoxyhemoglobin plus deoxyhemoglobin.
Here's an analysis of the acceptance criteria and study detailed in the provided document, addressing each of your requested points:
The document describes the GEM Premier 5000 device, an in vitro diagnostic system for analyzing blood gases and other parameters. The purpose of this specific 510(k) submission is to expand capillary heparinized whole blood claims for pCO2, potassium, chloride, hematocrit, and total hemoglobin. Therefore, the acceptance criteria and study focus on establishing the performance of these analytes with capillary samples on the GEM Premier 5000, demonstrating substantial equivalence to the predicate device (GEM Premier 4000).
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state "acceptance criteria" as a separate table. Instead, it demonstrates performance by showing that "All results met specification" for precision studies and by providing bias and Total Error (TEa) ranges for method comparison, which implicitly serve as acceptance criteria. For the regression analysis, the slope and intercept being close to 1 and 0 respectively, and a high correlation coefficient (r), are the performance indicators.
Here's a breakdown of the reported device performance for the analytes relevant to the expanded claims:
Precision Studies (Internal Precision - Capillary Transfer Samples)
(N=120 per analyte per level, 5 levels each)
| Analyte (Unit) | Level | Mean | Within Run SD | Within Run %CV |
|---|---|---|---|---|
| pCO2 (mmHg) | 1 | 9.9 | 0.5 | 5.1% |
| 2 | 34.5 | 0.6 | 1.9% | |
| 3 | 49.0 | 0.5 | 1.1% | |
| 4 | 68.9 | 1.6 | 2.3% | |
| 5 | 108.9 | 2.4 | 2.2% | |
| K+ (mmol/L) | 1 | 1.46 | 0.05 | 3.2% |
| 2 | 2.70 | 0.06 | 2.1% | |
| 3 | 5.43 | 0.04 | 0.8% | |
| 4 | 7.16 | 0.07 | 1.0% | |
| 5 | 17.29 | 0.15 | 0.9% | |
| Cl- (mmol/L) | 1 | 53.4 | 0.4 | 0.8% |
| 2 | 75.8 | 0.4 | 0.5% | |
| 3 | 89.8 | 0.4 | 0.4% | |
| 4 | 110.7 | 0.4 | 0.4% | |
| 5 | 152.8 | 0.7 | 0.4% | |
| Hct (%) | 1 | 19.3 | 0.6 | 2.9% |
| 2 | 32.8 | 0.6 | 1.9% | |
| 3 | 44.7 | 0.6 | 1.3% | |
| 4 | 55.0 | 0.8 | 1.5% | |
| 5 | 63.7 | 1.3 | 2.0% | |
| tHb (g/dL) | 1 | 7.02 | 0.16 | 2.3% |
| 2 | 11.06 | 0.09 | 0.8% | |
| 3 | 14.47 | 0.10 | 0.7% | |
| 4 | 17.34 | 0.09 | 0.5% | |
| 5 | 19.92 | 0.25 | 1.3% | |
| All results for these internal precision studies met specification. |
Precision Studies (Internal Precision - Capillary Finger-stick Samples)
(N=56 per analyte, single GEM Premier 5000, 2 POC operators, 28 donor samples)
| Analyte (Unit) | N | Mean | Within Sample SD | Within Sample %CV |
|---|---|---|---|---|
| pCO2 (mmHg) | 56 | 39 | 1.3 | 3.3 |
| K+ (mmol/L) | 56 | 4.1 | 0.11 | 2.6 |
| Cl- (mmol/L) | 56 | 106 | 0.3 | 0.3 |
| Hct (%) | 56 | 43 | 0.7 | 1.7 |
| tHb (g/dL) | 56 | 14.2 | 0.14 | 1.0 |
| All results for these internal precision studies met specification. |
Precision Studies (External POC Precision – Capillary Transfer Samples)
(N=minimum 20 residual whole blood samples over 5 days, triplicate runs, 3 POC operators)
| Analyte (Unit) | N | Mean | Within Sample SD | Within Sample %CV |
|---|---|---|---|---|
| pCO2 (mmHg) | 63 | 42 | 0.9 | 2.0 |
| 3 | 88 | 0.6 | 0.7 | |
| K+ (mmol/L) | 66 | 4.0 | 0.05 | 1.2 |
| Cl- (mmol/L) | 66 | 107 | 0.5 | 0.5 |
| Hct (%) | 66 | 30 | 0.7 | 2.4 |
| tHb (g/dL) | 60 | 11.0 | 0.29 | 2.6 |
| All results for these external POC precision studies met specification. |
Method Comparison (Pooled Point-of-Care Site and CSL Data with Native Capillary Samples)
(Reference: GEM Premier 4000)
| Analyte (Unit) | N | Range Min | Range Max | MDL | Bias at MDL | 95% CI of Bias at MDL | TEa Value (Implied Acceptance) |
|---|---|---|---|---|---|---|---|
| pCO2 (mmHg) | 130 | 26 | 50 | 35 | 1.0 | 1.0 to 2.0 | ± 5.0 |
| 50 | 1.0 | 1.0 to 2.0 | ± 5.0 | ||||
| 70 | 1.4% | 1.4% to 3.1% | ± 8% | ||||
| K+ (mmol/L) | 130 | 3.1 | 6.7 | 3.0 | 0.1 | -0.03 to 0.19 | ± 0.5 |
| 5.8 | 0.1 | 0.05 to 0.30 | ± 0.5 | ||||
| 7.5 | 1.3% | 0.7% to 6.8% | ± 7% | ||||
| Cl- (mmol/L) | 129 | 90 | 111 | 90 | -1.1% | -1.1% to 0.0% | ± 5% |
| 112 | -0.9% | -0.9% to 0.0% | ± 5% | ||||
| Hct (%) | 130 | 24 | 51 | 21 | -0.4 | -1.3 to 0.5 | ± 4 |
| 33 | -0.3 | -0.7 to 0.1 | ± 4 | ||||
| 56 | -0.1 | -0.7 to 0.5 | ± 4 | ||||
| tHb (g/dL) | 131 | 6.9 | 17.3 | 7.0 | -0.27 | -0.43 to -0.12 | ± 0.7 |
| 10.5 | -0.17 | -0.25 to -0.09 | ± 0.7 | ||||
| 18.0 | 0.05 | -0.07 to 0.16 | ± 1.0 |
Method Comparison (Pooled Point-of-Care Site and CSL Data with Additional Contrived Capillary Results - Regression Analysis)
(Reference: GEM Premier 4000)
| Analyte (Unit) | N | Slope | Intercept | r | Sample Range |
|---|---|---|---|---|---|
| pCO2 (mmHg) | 139 | 1.000 | 1.000 | 0.980 | 11 to 87 |
| K+ (mmol/L) | 140 | 1.000 | 0.100 | 0.995 | 1.5 to 17.6 |
| Cl- (mmol/L) | 141 | 1.000 | -1.000 | 0.995 | 45 to 149 |
| Hct (%) | 136 | 1.003 | -0.407 | 0.987 | 15 to 64 |
| tHb (g/dL) | 137 | 1.028 | -0.470 | 0.994 | 4.5 to 20.5 |
Implied Acceptance Criteria:
- Precision: Standard Deviation (SD) and Coefficient of Variation (%CV) values for each analyte at various levels must meet an internal "specification" (not explicitly stated in the table, but indicated as "All results met specification."). The document mentions analysis being separated for "fixed acceptance criteria range (SD)" and "variable acceptance criteria range (%CV)".
- Method Comparison (Bias): The observed biases at the medical decision levels and their 95% Confidence Intervals (CI) should be within the Total Error (TEa) values provided.
- Method Comparison (Regression): Slope close to 1, intercept close to 0, and a high correlation coefficient (r) (typically >0.975 for quantitative assays).
2. Sample Size Used for the Test Set and Data Provenance
The test sets were derived from various sources:
- Internal Precision - Capillary Transfer Samples:
- Sample Size: 5 different concentrations of whole blood per analyte, each run on 3 analyzers for 5 days, 1 run/day, 8 replicates/run/level. Total N = 120 per analyte per level.
- Data Provenance: Internal laboratory setting. Samples were "whole blood... transferred from syringe to a capillary device," implying controlled, possibly contrived, whole blood samples.
- Internal Precision - Capillary Finger-stick Samples:
- Sample Size: 28 donor samples, each collected into 2 capillary tubes and run in singlicate. Total N = 56 for each analyte (28 donors * 2 samples).
- Data Provenance: "IL Customer Simulation Laboratory (CSL), using finger-stick samples drawn and run by two (2) point-of-care (POC) operators." This indicates a prospective collection of real human samples in a simulated clinical environment.
- External POC Precision - Capillary Transfer Samples:
- Sample Size: Minimum of 20 residual whole blood samples run over 5 days, each run in triplicate. Total N = 60-66 samples per analyte (e.g., 63 for pCO2 for main range, 3 for high range; 66 for K+ and Cl-; 60 for tHb).
- Data Provenance: "External point-of-care (POC) site, using heparinized whole blood patient samples transferred from syringe to a capillary device and run by three (3) POC operators." This suggests prospective collection of residual patient samples in a real clinical POC setting.
- Point-of-Care (POC) Method Comparison - Native Capillary Finger-stick Samples:
- Sample Size: Minimum of 40 native capillary samples from an external POC site + minimum of 80 native samples from IL CSL. Total N = 129-131 samples for each analyte.
- Data Provenance: "Native capillary finger-stick samples... collected via finger-stick by six (6) POC operators at an external POC site... and three (3) POC operators in the IL internal Customer Simulation Laboratory (CSL)." This is a prospective collection of real human finger-stick samples from both real-world POC and simulated environments.
- Point-of-Care (POC) Method Comparison - Pooled Data (Regression Analysis):
- Sample Size: The native capillary samples (N=129-131) were pooled with "contrived whole blood samples (< 10%) prepared internally to span the claimed reportable range." Total N = 136-141 samples for each analyte.
- Data Provenance: A mix of prospectively collected native human samples (from external POC and CSL) and internally prepared contrived samples.
No specific country of origin for the human data is explicitly stated. Given "Instrumentation Laboratory Co." is based in Bedford, MA, USA, it's reasonable to infer the studies likely took place in the USA.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
The document does not describe the use of "experts" to establish a ground truth in the way one might for image interpretation or diagnosis. Instead, the ground truth for performance studies of in-vitro diagnostic devices for quantitative measurements like PCO2, K+, etc., is established:
- For Precision studies: By the instrument itself and its internal consistency.
- For Method Comparison studies: By a predicate device (GEM Premier 4000), which is itself an FDA-cleared device. The "ground truth" is the measurement provided by the established, legally marketed predicate device.
- Operators: The studies involved "two (2) point-of-care (POC) operators" for internal finger-stick precision, "three (3) POC operators" for external POC transfer precision, and "six (6) POC operators at an external POC site" and "three (3) POC operators in the IL internal Customer Simulation Laboratory (CSL)" for the method comparison study. While these are healthcare professionals, they are operating the devices, not acting as "experts" adjudicating clinical ground truth.
4. Adjudication Method for the Test Set
No explicit adjudication method (like 2+1 or 3+1) is mentioned or applicable here. For quantitative IVD devices when comparing to a predicate, the comparison is direct between the numerical outputs of the new device and the predicate device. Where there are multiple operators, their data is pooled or analyzed for variability, but not "adjudicated" in the sense of reaching a consensus on a diagnosis.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size of Human Improvement
No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. This type of study (often used for imaging devices where human interpretation is assisted by AI) is not relevant for this device, which provides direct quantitative measurements of blood parameters. The device itself performs the analysis; it does not assist human "readers" in making a diagnosis from images or complex data.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Yes, the performance studies described are essentially standalone algorithm performance (instrument only). The operators are introducing the sample and initiating the test, but the measurement and analysis are performed by the device (its embedded algorithms and sensors) without human interpretation or intervention in the measurement process itself. The precision studies and method comparison directly assess the device's measurement accuracy and reproducibility.
7. The Type of Ground Truth Used
The ground truth used for proving substantial equivalence is:
- Predicate Device Measurements: For method comparison studies, the measurements obtained from the FDA-cleared GEM Premier 4000 device served as the comparative "ground truth." This is a common approach for 510(k) submissions seeking substantial equivalence for new IVD devices.
- Internal Specifications/Reference Materials: For precision and linearity studies, the device performance is evaluated against its own internal specifications and, implicitly, against calibrated reference materials that define precise analyte concentrations.
8. The Sample Size for the Training Set
The document does not specify a training set. This is because the GEM Premier 5000 is an in vitro diagnostic (IVD) device that performs direct measurements based on established electrochemical and optical principles. It does not use machine learning or AI models that typically require a distinct "training set" of data in the same way an AI-based image analysis tool would.
The document mentions "cartridge EEPROM coefficient adjustments (for pCO2, potassium and hematocrit)" were implemented. These adjustments involve recalibrating the device parameters, which might be informed by historical performance data or initial development tests, but these are not typically referred to as a "training set" in the context of IVD devices.
9. How the Ground Truth for the Training Set Was Established
Since a "training set" in the context of machine learning/AI is not applicable or specified, the concept of establishing ground truth for it is also not applicable here. The device's foundational measurement principles and calibration are based on established analytical chemistry and physics.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
December 29, 2017
Instrumentation Laboratory Co. Carol Marble Regulatory Affairs Director 180 Hartwell Road Bedford, MA 01730
Re: K173403
Trade/Device Name: GEM Premier 5000 Regulation Number: 21 CFR 862.1120 Regulation Name: Blood gases (pCO2, pO2) and blood pH test system Regulatory Class: Class II Product Code: CHL, CEM, CGZ, GKF, GKR, GLY Dated: October 30, 2017 Received: October 31, 2017
Dear Carol Marble:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing, practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR
{1}------------------------------------------------
Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Kellie B. Kelm -S
for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known)
K173403
Device Name
GEM Premier 5000
Indications for Use (Describe)
The GEM Premier 5000 is a portable critical care system for use by health care professionals to rapidly analyze heparinized whole blood samples at the point of health care delivery in a clinical setting and in a central laboratory. The instrument provides quantitative measurements of pH, pCO2, sodium, potassium, chloride, ionized calcium, glucose, lactate, hematocrit, total bilirubin and CO-Oximetry (tHb, 02Hb, MetHb, HHb, sO2*) parameters from arterial, venous or capillary heparinized whole blood. These parameters, along with derived parameters, aid in the diagnosis of a patient's acid/base status, electrolyte and metabolite balance and oxygen delivery capacity. *sO2 = ratio between the concentration of oxyhemoglobin and oxyhemoglobin plus deoxyhemoglobin.
· pH, pCO2, and pO2 measurements in whole blood are used in the diagnosis and treatment of life-threatening acid-base disturbances.
· Electrolytes in the human body have multiple roles. Nearly all metabolic processes depend on or vary with electrolytes:
· Sodium (Na+) measurements are used in the diagnosis and treatment of aldosteronism, diabetes insipidus, adrenal hypertension, Addison's disease, dehydration, inappropriate antidiuretic secretion, or other diseases involving electrolyte imbalance.
· Potassium (K+) measurements are used to monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.
• Ionized calcium (Ca++) measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.
• Chloride (Cl-) measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders, such as cystic fibrosis and diabetic acidosis.
· Hematocrit (Het) measurements in whole blood of the packed red cell volume of a blood sample are used to distinguish normal from abnormal states, such as anemia and erythrocytosis (an increase in the number of red cells),
· Glucose (Glu) measurement is used in the diagnosis, monitoring and treatment of carbohydrate metabolism disturbances including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma.
· Lactate (Lac) measurement is used:
· to evaluate the acid-base status of patients suspected of having lactic acidosis;
· to monitor tissue hypoxia and strenuous physical exertion:
· in the diagnosis of hyperlactatemia.
· Total Bilirubin (tBili) measurement is used to aid in assessing the risk of kernicterus and hyperbilirulyinemia in neonates.
• CO-Oximetry (tHb, COHb, MetHb, O2Hb, HHb, and sO2) evaluates the ability of the blood to carry oxygen by measuring total hemoglobin and determining the percentage of functional hemoglobin species.
• Total Hemoglobin (tHb): Total hemoglobin measure the hemoglobin content of whole blood for the detection of anemia.
· COHb: Carboxyhemoglobin measurements are used to determine the carboxyhemoglobin content of human blood as an aid in the diagnosis of carbon monoxide poisoning.
Type of Use (Select one or both, as applicable)
[x] Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
{3}------------------------------------------------
Indications for Use
510(k) Number (if known)
Device Name
GEM Premier 5000
Indications for Use (Describe)
- · MetHb: Methemoglobin measurements are used to determine different conditions of methemoglobinemia.
- · HHb: Deoxyhemoglobin, as a fraction of total hemoglobin, is used in combination with oxyhemoglobin to measure oxygen status.
- · O2Hb: Oxyhemoglobin, as a fraction of total hemoglobin, is used in combination with decxyhemoglobin to measure oxygen status.
- · sO2: Oxygen saturation, more specifically the ratio between the concentration of oxyhemoglobin and oxyhemoglobin plus deoxyhemoglobin, is used to measure oxygen status.
Type of Use (Select one or both, as applicable)
V Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
{4}------------------------------------------------
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows the logo for Instrumentation Laboratory, a Werfen Company. The logo consists of a stylized "W" shape in shades of blue and green, followed by the text "Instrumentation Laboratory" in a dark gray sans-serif font. Below the company name, in a smaller font size, is the text "A Werfen Company".
K173403
510(k) Summary
This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and 21 CFR 807.92.
| Submitter's Information | Instrumentation Laboratory (IL) Co.180 Hartwell RoadBedford, MA 01730, USA |
|---|---|
| Contact Person | Carol Marble, Regulatory Affairs DirectorPhone: 781-861-4467Fax: 781-861-4207Email: cmarble@ilww.com |
| Preparation Date | December 19, 2017 |
| Device Trade Name | GEM Premier 5000 |
| Regulatory Information | ||||
|---|---|---|---|---|
| Analyte | RegulationSection | Regulatory Description | Class | ProductCode |
| $pCO_2$ | 862.1120 | Blood Gases ( $pCO_2$ , $pO_2$ ) and Blood pH system | II | CHL |
| Potassium | 862.1600 | Potassium test system | II | CEM |
| Chloride | 862.1170 | Chloride test system | II | CGZ |
| Hematocrit | 864.5600 | Automated hematocrit instrument | II | GKF |
| Total Hemoglobin | 864.5620 | Automated hemoglobin system | II | GKR |
| 864.7500 | Whole blood hemoglobin assays | II | GLY |
Device Description
The GEM Premier 5000 system provides health care professionals with fast, accurate, quantitative measurements of pH, pCO2, pO2, sodium, potassium, chloride, ionized calcium, glucose, lactate, hematocrit, total bilirubin and CO-Oximetry (tHb, O₂Hb, MetHb, HHb, sO₂*) parameters from arterial, venous or capillary heparinized whole blood in central laboratory or point-of-care clinical settings.
*sO2 = Ratio between the concentration of oxyhemoglobin plus deoxyhemoglobin plus deoxyhemoglobin.
{6}------------------------------------------------
Purpose for Submission
The purpose of this submission is to expand capillary heparinized whole blood claims on the GEM Premier 5000 system to include the following analytes: pCQz, potassium, chloride, hematocrit and total hemoglobin.
- Note: The other measured analytes on the GEM Premier 5000 were previously FDA cleared for capillary claims under their respective 510(k): K160225, K160402, K160412 and K160415.
To support the expanded claims, a combination of improved sample handling instructions in the labeling to avoid pre-analytical error and cartridge EEPROM coefficient adjustments (for pCO2, potassium and hematocrit) were implemented on the GEM Premier 5000.
Intended Use / Indications for Use
The GEM Premier 5000 is a portable critical care system for use by health care professionals to rapidly analyze heparinized whole blood samples at the point of health care delivery in a clinical setting and in a central laboratory. The instrument provides quantitative measurements of pH, pCQ2, pO2, sodium, potassium, chloride, ionized calcium, glucose, lactate, hematocrit, total bilirubin and CO-Oximetry (tHb, O₂Hb, COHb, MetHb, HHb, sO-*) parameters from arterial, venous or capillary heparinized whole blood. These parameters, along with derived parameters, aid in the diagnosis of a patient's acid/base status, electrolyte and metabolite balance and oxygen delivery capacity.
*s02 = ratio between the concentration of oxyhemoglobin plus deoxyhemoglobin plus deoxyhemoglobin.
- . pH, pCO2, and pO2 measurements in whole blood are used in the diagnosis and treatment of lifethreatening acid-base disturbances.
- . Electrolytes in the human body have multiple roles. Nearly all metabolic processes depend on or vary with electrolytes:
- . Sodium (Na*) measurements are used in the diagnosis and treatment of aldosteronism, diabetes insipidus, adrenal hypertension, Addison's disease, dehydration, inappropriate antidiuretic secretion, or other diseases involving electrolyte imbalance.
- Potassium (K*) measurements are used to monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.
- . lonized calcium (Ca*) measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.
- Chloride (Cl) measurements are used in the diagnosis and treatment of electrolyte and metabolic . disorders, such as cystic fibrosis and diabetic acidosis.
{7}------------------------------------------------
Intended Use / Indications for Use (Cont.)
- Hematocrit (Hct) measurements in whole blood of the packed red cell volume of a blood sample are used to distinguish normal from abnormal states, such as anemia and erythrocytosis (an increase in the number of red cells).
- Glucose (Glu) measurement is used in the diagnosis, monitoring and treatment of carbohydrate metabolism disturbances including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma.
- Lactate (Lac) measurement is used:
- . to evaluate the acid-base status of patients suspected of having lactic acidosis;
- . to monitor tissue hypoxia and strenuous physical exertion;
- . in the diagnosis of hyperlactatemia.
- Total Bilirubin (tBili) measurement is used to aid in assessing the risk of kernicterus and hyperbilirubinemia in neonates.
- CO-Oximetry (tHb, COHb, MetHb, O2Hb, HHb, and sO2) evaluates the ability of the blood to carry oxygen by measuring total hemoglobin and determining the percentage of functional and dysfunctional hemoglobin species.
- . Total Hemoglobin (tHb): Total hemoglobin measurements are used to measure the hemoglobin content of whole blood for the detection of anemia.
- . COHb: Carboxyhemoglobin measurements are used to determine the carboxyhemoglobin content of human blood as an aid in the diagnosis of carbon monoxide poisoning.
- . MetHb: Methemoglobin measurements are used to determine different conditions of methemoglobinemia.
- . HHb: Deoxyhemoglobin, as a fraction of total hemoglobin, is used in combination with oxyhemoglobin to measure oxygen status.
- . O2Hb: Oxyhemoglobin, as a fraction of total hemoglobin, is used in combination with deoxyhemoglobin to measure oxygen status.
- . sO2: Oxygen saturation, more specifically the ratio between the concentration of oxyhemoglobin and oxyhemoglobin plus deoxyhemoglobin, is used to measure oxygen status.
{8}------------------------------------------------
Substantial Equivalence
The following table compares the use of capillard whole blood samples with pCO2, potasium, chloride, hemoglobin on the GEM Premier 5000 to the predicate device, the GEM Premier 4000.
| ltem | Predicate Device | New Device | |
|---|---|---|---|
| Trade Name | GEM Premier 4000 | GEM Premier 5000 | |
| 510(k) No. | K133407 | Pending | |
| Manufacturer | Instrumentation Laboratory Co. | Instrumentation Laboratory Co. | |
| Intended Use /Indications forUse | The GEM Premier 4000 is a portable critical care system for use byhealth care professionals to rapidly analyze whole blood samples atthe point of health care delivery in a clinical setting and in a centrallaboratory. The instrument provides quantitative measurements ofpH, pCO2, pO2, sodium, potassium, chloride, ionized calcium, glucose,lactate, hematocrit, total bilirubin and CO-Oximetry (tHb, O2Hb,COHb, MetHb, HHb) parameters. Total bilirubin can also bequantitated from heparinized plasma samples when analyzed in thetBili/CO-Ox mode.These parameters, along with derivedparameters, aid in the diagnosis of a patient's acid/base status,electrolyte and metabolite balance and oxygen delivery capacity.Total bilirubin measurements are used in the diagnosis andmanagement of biliary tract obstructions, liver disease and varioushemolytic diseases and disorders involving the metabolism ofbilirubin. In neonates, the level of total bilirubin is used to aid inassessing the risk of kernicterus. | The GEM Premier 5000 is a portable critical care system for useby health care professionals to rapidly analyze heparinized wholeblood samples at the point of health care delivery in a clinicalsetting and in a central laboratory. The instrument providesquantitative measurements of pH, pCO2, pO2, sodium, potassium,chloride, ionized calcium, glucose, lactate, hematocrit, totalbilirubin and CO-Oximetry (tHb, O2Hb, COHb, MetHb, HHb, sO2*)parameters from arterial, venous or capillary heparinized wholeblood. These parameters, along with derived parameters, aid inthe diagnosis of a patient's acid/base status, electrolyte andmetabolite balance and oxygen delivery capacity.*sO2 = ratio between the concentration of oxyhemoglobin andoxyhemoglobin plus deoxyhemoglobin.See previous pages for complete Intended Use/Indications for Usefor the GEM Premier 5000. | |
| Substantial Equivalence (Cont.) | |||
| Item | Predicate Device | Modified Device | |
| Trade Name | GEM Premier 4000K133407 | GEM Premier 5000 | |
| Intended Settings | Central Laboratory and Point-of-Care | Same | |
| Sample Type | Heparinized whole blood(arterial, venous or capillary) | Same; expanding capillaryclaims to pCO2, K+, Cl-, Hctand tHb with this 510(k) | |
| Detection Method | Analyte | GEM Premier 4000 | GEM Premier 5000 |
| pCO2 | Potentiometry | Same | |
| K+ | Potentiometry | Same | |
| Cl- | Potentiometry | Same | |
| Hct | Conductivity | Same | |
| tHb | Spectrophotometry | Same | |
| Sample Introduction | Aspiration | Same | |
| PAK Shelf-Life Stability | Up to 180 days | Same | |
| PAK Storage Temperature | 15-25°C | Same | |
| System Operating Temperature | 12-32°C | Same | |
| Operating System Software | Linux-based | Same | |
| Calibration | 2-point calibration | Same | |
| Reportable Range | Analyte | GEM Premier 4000 | GEM Premier 5000 |
| pCO2 | 6 to 125 mmHg | 6 to 125 mmHg | |
| K+ | 0.2 to 19.0 mmol/L | 1.0 to 19.0 mmol/L | |
| Cl- | 40 to 158 mmol/L | 40 to 158 mmol/L | |
| Hct | 15 to 72% | 15 to 72% | |
| tHb | 3.0 to 23.0 g/dL | 3.0 to 23.0 g/dL |
{9}------------------------------------------------
{10}------------------------------------------------
Performance Summary
- The linearity, limit of detection and analytical specificity performance for pCO₂, K*, Cl , Hct and tHb Note: on the GEM Premier 5000 were previously established under K160225, K160415 for heparinized whole blood and these studies are also applicable for capillary heparinized whole blood. Consequently, studies performed were limited to precision and method comparison to support substantial equivalence for these analytes with capillary samples.
Internal Precision - Capillary Transfer Samples
In accordance with CLSI EP05-A3, an internal precision study was performed using five (5) different concentrations of whole blood per analyte, each run on three (3) GEM Premier 5000 analyzers per sample level for five (5) days, with one (1) run per day and eight (8) replicates measured per run per level (N=120 per analyte per level). Samples were transferred from syringe to a capillary device.
| Analyte | Level | Mean | N | Within RunSD | Within Run%CV | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pCO2(mmHg) | 1 | 9.9 | 120 | 0.5 | 5.1% | ||||||||||||||||||||
| 2 | 34.5 | 120 | 0.6 | 1.9% | |||||||||||||||||||||
| 3 | 49.0 | 120 | 0.5 | 1.1% | |||||||||||||||||||||
| 4 | 68.9 | 120 | 1.6 | 2.3% | |||||||||||||||||||||
| 5 | 108.9 | 120 | 2.4 | 2.2% | |||||||||||||||||||||
| K+(mmol/L) | 1 | 1.46 | 120 | 0.05 | 3.2% | ||||||||||||||||||||
| 2 | 2.70 | 120 | 0.06 | 2.1% | |||||||||||||||||||||
| 3 | 5.43 | 120 | 0.04 | 0.8% | |||||||||||||||||||||
| 4 | 7.16 | 120 | 0.07 | 1.0% | |||||||||||||||||||||
| 5 | 17.29 | 120 | 0.15 | 0.9% | |||||||||||||||||||||
| Cl-(mmol/L) | 1 | 53.4 | 120 | 0.4 | 0.8% | 2 | 75.8 | 120 | 0.4 | 0.5% | 3 | 89.8 | 120 | 0.4 | 0.4% | 4 | 110.7 | 120 | 0.4 | 0.4% | 5 | 152.8 | 120 | 0.7 | 0.4% |
| Cl-(mmol/L) | 1 | 53.4 | 120 | 0.4 | 0.8% | ||||||||||||||||||||
| 2 | 75.8 | 120 | 0.4 | 0.5% | |||||||||||||||||||||
| 3 | 89.8 | 120 | 0.4 | 0.4% | |||||||||||||||||||||
| 4 | 110.7 | 120 | 0.4 | 0.4% | |||||||||||||||||||||
| 5 | 152.8 | 120 | 0.7 | 0.4% |
All results met specification.
{11}------------------------------------------------
| Analyte | Level | Mean | N | Within Run SD | Within Run %CV |
|---|---|---|---|---|---|
| Hct(%) | 1 | 19.3 | 120 | 0.6 | 2.9% |
| 2 | 32.8 | 120 | 0.6 | 1.9% | |
| 3 | 44.7 | 120 | 0.6 | 1.3% | |
| 4 | 55.0 | 120 | 0.8 | 1.5% | |
| 5 | 63.7 | 120 | 1.3 | 2.0% | |
| tHb(g/dL) | 1 | 7.02 | 120 | 0.16 | 2.3% |
| 2 | 11.06 | 120 | 0.09 | 0.8% | |
| 3 | 14.47 | 120 | 0.10 | 0.7% | |
| 4 | 17.34 | 120 | 0.09 | 0.5% | |
| 5 | 19.92 | 120 | 0.25 | 1.3% |
Internal Precision – Capillary Transfer Samples (Cont.):
{12}------------------------------------------------
Internal Precision – Capillary Finger-stick Samples
An internal precision study was performed on a single GEM Premier 5000 in the IL Customer Simulation Laboratory (CSL), using finger-stick samples drawn and run by two (2) point-of-care (POC) operators brought on site for the study.
The study used twenty-eight (28) donor samples, collected into two (2) capillary tubes via capillary puncture. Each capillary tube was run in singlicate.
Results were analyzed separately for samples with mean within the fixed acceptance criteria range (SD) and those in the variable acceptance criteria range (%CV).
All results met specification.
| Analyte | N | Mean | Within SampleSD | Within Sample%CV |
|---|---|---|---|---|
| pCO2(mmHg) | 56 | 39 | 1.3 | 3.3 |
| K+(mmol/L) | 56 | 4.1 | 0.11 | 2.6 |
| Cl-(mmol/L) | 56 | 106 | 0.3 | 0.3 |
| Hct(%) | 56 | 43 | 0.7 | 1.7 |
| tHb(g/dL) | 56 | 14.2 | 0.14 | 1.0 |
{13}------------------------------------------------
External POC Precision – Capillary Transfer Samples
A precision study was performed on a GEM Premier 5000 at an external point-of-care (POC) site, using heparinized whole blood patient samples transferred from syringe to a capillary device and run by three (3) POC operators.
The study used a minimum of twenty (20) residual whole blood samples run over five (5) days. Each sample was run in triplicate.
Results were analyzed separately for samples with mean within the fixed acceptance criteria range (SD) and those in the variable acceptance criteria range (%CV).
All results met specification.
| Analyte | N | Mean | Within SampleSD | Within Sample%CV |
|---|---|---|---|---|
| pCO2(mmHg) | 63 | 42 | 0.9 | 2.0 |
| pCO2(mmHg) | 3 | 88 | 0.6 | 0.7 |
| K+(mmol/L) | 66 | 4.0 | 0.05 | 1.2 |
| Cl-(mmol/L) | 66 | 107 | 0.5 | 0.5 |
| Hct(%) | 66 | 30 | 0.7 | 2.4 |
| tHb(g/dL) | 60 | 11.0 | 0.29 | 2.6 |
{14}------------------------------------------------
Point-of-Care (POC) Method Comparison
A method comparison study was conducted comparing the GEM Premier 5000 to the GEM Premier 4000 (predicate device) with native capillary finger-stick samples were collected via finger-stick by six (6) POC operators at an external POC site (minimum of 40 native capillary samples) and three (3) POC operators in the IL internal Customer Simulation Laboratory (CSL) (minimum of 80 native samples), and then run in singlicate on both the test and predicate instruments.
| Pooled Point-of-Care Site and CSL Data with Native Capillary Samples | |||||||
|---|---|---|---|---|---|---|---|
| Analyte | N | RangeMin | RangeMax | MDL | Bias atMDL | 95% CI of Bias at MDL | TEa |
| pCO2(mmHg) | 130 | 26 | 50 | 35 | 1.0 | 1.0 to 2.0 | ± 5.0 |
| 50 | 1.0 | 1.0 to 2.0 | ± 5.0 | ||||
| 70 | 1.4% | 1.4% to 3.1% | ± 8% | ||||
| K+(mmol/L) | 130 | 3.1 | 6.7 | 3.0 | 0.1 | -0.03 to 0.19 | ± 0.5 |
| 5.8 | 0.1 | 0.05 to 0.30 | ± 0.5 | ||||
| 7.5 | 1.3% | 0.7% to 6.8% | ± 7% | ||||
| Cl(mmol/L) | 129 | 90 | 111 | 90 | -1.1% | -1.1% to 0.0% | ± 5% |
| 112 | -0.9% | -0.9% to 0.0% | ± 5% | ||||
| Hct(%) | 130 | 24 | 51 | 21 | -0.4 | -1.3 to 0.5 | ± 4 |
| 33 | -0.3 | -0.7 to 0.1 | ± 4 | ||||
| 56 | -0.1 | -0.7 to 0.5 | ± 4 | ||||
| tHb(g/dL) | 131 | 6.9 | 17.3 | 7.0 | -0.27 | -0.43 to -0.12 | ± 0.7 |
| 10.5 | -0.17 | -0.25 to -0.09 | ± 0.7 | ||||
| 18.0 | 0.05 | -0.07 to 0.16 | ± 1.0 |
The observed biases at the medical decision levels are shown below:
{15}------------------------------------------------
Point-of-Care (POC) Method Comparison (Cont.)
The data from the native capillary samples (finger-stick samples) previously presented were pooled with contrived whole blood samples (< 10%) prepared internally to span the claimed reportable range.
The regression analysis is shown below for each analyte:
| Pooled Point-of-Care Site and CSL Data with Additional Contrived Capillary Results | |||||
|---|---|---|---|---|---|
| Analyte | N | Slope | Intercept | r | Sample Range |
| pCO2 (mmHg) | 139 | 1.000 | 1.000 | 0.980 | 11 to 87 |
| K+ (mmol/L) | 140 | 1.000 | 0.100 | 0.995 | 1.5 to 17.6 |
| Cl- (mmol/L) | 141 | 1.000 | -1.000 | 0.995 | 45 to 149 |
| Hct (%) | 136 | 1.003 | -0.407 | 0.987 | 15 to 64 |
| tHb (g/dL) | 137 | 1.028 | -0.470 | 0.994 | 4.5 to 20.5 |
Conclusion
Based on the substantial equivalence comparison and the results of the conducted performance evaluations, it was concluded that the performance of ρCO₂, potassium, chloride, hematocrit and total hemoglobin with capillary samples on the GEM Premier 5000 is as safe and effective as on the predicate device.
§ 862.1120 Blood gases (P
CO2 , PO2 ) and blood pH test system.(a)
Identification. A blood gases (PCO2 , PO2 ) and blood pH test system is a device intended to measure certain gases in blood, serum, plasma or pH of blood, serum, and plasma. Measurements of blood gases (PCO2 , PO2 ) and blood pH are used in the diagnosis and treatment of life-threatening acid-base disturbances.(b)
Classification. Class II.